(Press-News.org) A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University.
Of the 1,115 patients who took part in the trial, 68 per cent relapsed on the new treatment within three years, compared with 76 per cent of those who had the standard treatment. And 25 per cent were still alive after three years, compared with 20 per cent of those who had the standard treatment.
The drug – called Gemtuzumab Ozogamicin (GO) – is part of a new class of 'antibody conjugate' drugs, which involve attaching chemotherapy molecules to antibodies specifically designed to recognise proteins on the surface of cancer cells, thereby targeting the cancer while leaving healthy cells unharmed.
The results of the trial show that adding GO to treatment could improve the effectiveness of chemotherapy without excessively increasing side effects, providing a potential lifeline for older AML patients who are often too frail to tolerate more intensive chemotherapy regimes.
The results are published in the Journal of Clinical Oncology.
Chief investigator Professor Alan Burnett, School of Medicine, said: "These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
"Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years."
Trial participants were recruited at 149 hospitals around the UK and Denmark. All patients had been recently diagnosed with either AML or high risk myelodysplastic syndrome, which can develop into AML, and the majority were aged over 60. Each patient was randomly assigned to receive one of two standard chemotherapy regimes, either with or without GO.
Kate Law, Cancer Research UK's director of clinical research, said: "In general the outlook for leukaemia patients has improved dramatically in recent decades. But when leukaemia is diagnosed in older people it's much harder to treat and there is a real need for effective treatments that are suitable for this age group.
"Importantly this new trial shows that GO may have particular benefits for patients over 60, who may be unsuitable for other more intensive treatments. This is good news and we are now looking to see if these results can be replicated in younger patients."
INFORMATION:
Smart drug improves survival in older patients with acute myeloid leukemia
2012-11-12
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Place in the sun carries risks for outdoor workers
2012-11-12
Those individuals who work outdoors with resultant sun exposure are at increased risk for non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma. Manigé Fartasch shows that the connection between occupational UV exposure and squamous cell carcinoma is now well-established in her review article in issue 43 of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2012; 109(43): 715−20).
The results are less clear for basal cell carcinoma, another form of non-melanoma skin cancer. Skin cancers caused by UV light have not yet been considered ...
The consequences of late preterm birth
2012-11-12
Delivery at any time before the 39th week of gestation increases the risk of postnatal problems and mortality. A team of authors headed by Christian F. Poets has analyzed mortality and morbidity data from epidemiological studies of infants born between two and six weeks preterm, comparing them with infants born at full term. They present their findings in issue 43 of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2012; 109(43): 721−6).
As a rule, elective Cesarean sections are performed somewhat before full term, in order to prevent spontaneous delivery. However, ...
Ultrasound gel and infections: Researchers propose guidelines to reduce risk
2012-11-12
CHICAGO (November 12, 2012) – In the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, guidelines have been proposed by epidemiologists from Beaumont Health System to reduce the risk of infection from contaminated gels. The recommendations are based on the authors' own experiences with an outbreak traced to contaminated ultrasound transmission gel.
In December 2011, researchers uncovered an unusual cluster of Pseudomonas aeruginosa in a cardiovascular surgery intensive care unit during routine ...
Study justifies L-DOPA therapy for Angelman syndrome
2012-11-12
CHAPEL HILL, N.C. – Last year a clinical trial of L-DOPA -- a mainstay of Parkinson's disease therapy -- was launched for Angelman syndrome, a rare intellectual disorder that shares similar motor symptoms such as tremors and difficulty with balance. The clinical trial is based on a 10-year-old case report showing benefit with the drug, but few studies since have explored the neurological justification for using L-DOPA to treat parkinsonian features in Angelman syndrome.
New research from the University of North Carolina School of Medicine, conducted in animal models ...
Patients shy away from asking healthcare workers to wash hands
2012-11-12
CHICAGO (November 12, 2012) – According to a new study published online today, most patients at risk for healthcare-associated infections (HAIs) agree that healthcare workers should be reminded to wash their hands, but little more than half would feel comfortable asking their physicians to wash. The study is published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. The study points to the need for patient empowerment to improve hand hygiene of healthcare workers.
Researchers from ...
PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
2012-11-12
PHILADELPHIA — The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research.
Triple-negative breast cancers do not express three common targets of breast cancer treatments: the estrogen receptor, progesterone receptor and HER2/neu. As a result, women with triple-negative breast cancer have few treatment options. In ...
UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
2012-11-12
Rapid mutation has long been considered a key to viral adaptation to environmental change. But in the case of the coronavirus responsible for deadly severe acute respiratory syndrome (SARS), collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations cripples the virus's ability to cause disease in animals. In addition, they say this finding may allow scientists to explore a new option for creating safer live vaccines.
A collaborative study, published Nov. 11 in Nature Medicine, demonstrates ...
Bringing measuring accuracy to radical treatment
2012-11-12
An international team of scientists working at the Plasma Technology research unit at Ghent University, Belgium, has determined for the first time the absolute density of active substances called radicals found in a state of matter known as plasma, in a study about to be published in EPJ D. These findings could have important implications for medicine—for example, for stimulating tissue regeneration, or to induce a targeted antiseptic effect in vivo without affecting neighbouring tissues.
Qing Xiong and colleagues utilised laser fluorescence spectroscopy (LIF), a detection ...
Duke Medicine news -- Genome sequencing of Burkitt Lymphoma reveals unique mutation
2012-11-12
DURHAM, N.C. – In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and a new one that was unique to the disease.
Findings from the genetic sequencing of Burkitt lymphoma, an aggressive form of lymphoma, could be used to develop new drugs or aim existing therapies at mutations known to be susceptible. The researchers published their findings online Sunday, Nov. 11, 2012, in the journal Nature Genetics.
"This ...
News from Annals of Internal Medicine
2012-11-12
Philadelphia, November 12, 2012 – A new article being published early online in Annals of Internal Medicine describes the diagnosis and treatment protocol established in a Roanoke, Va. hospital to care for dozens of patients presenting with suspected fungal meningitis related to contaminated epidural spinal injections. This unprecedented surge of patients seeking care for a rare central nervous system (CNS) infection required physicians to react quickly with little data to guide treatment decisions. The authors suggest that the data collected from these cases may fill information ...